Biological Drugs in Guillain-Barré Syndrome: An Update

Authors

Nazgol Motamed-Gorji, School of Medicine, Tehran University of Medical Sciences, Tehran. Iran.
Nassim Matin, Department of Neurology, Massachusetts General Hospital, Boston, MA. United States.
Omidreza Tabatabaie, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. United States.
Piero Pavone, General Paediatrics Operative Unit, Policlinico-Vittorio Emanuele University Hospital, University of Catania, Catania. Italy.
Catia Romano, General Paediatrics Operative Unit, Policlinico-Vittorio Emanuele University Hospital, University of Catania, Catania. Italy.
Raffaele Falsaperla, General Paediatrics Operative Unit, Policlinico-Vittorio Emanuele University Hospital, University of Catania, Catania. Italy.
Giovanna Vitaliti, General Paediatrics Operative Unit, Policlinico-Vittorio Emanuele University Hospital, University of Catania, Catania. Italy.

Document Type

Article

Abstract

BACKGROUND: Guillain-Barré Syndrome (GBS) is currently considered the most common global cause of acute flaccid paralysis. Currently, standard therapy for Guillain-Barré Syndrome includes intravenous immunoglobulin or plasma exchange. Despite medical advances regarding these treatments, many treated patients do not reach full recovery. Therefore several biological agents have attracted the attentions from researchers during the last decades, and various studies have investigated their role in Guillain-Barré Syndrome. OBJECTIVE: The present study aims to address emerging biological approaches to GBS while considering their efficiency and safety in treating the disease. MATERIALS AND METHODS: An extensive electronic literature search was conducted by two researchers from April 2016 to July 2016. Original articles, clinical trials, systematic reviews (with or without meta-analysis) and case reports were selected. Titles and abstracts of papers were screened by reviewers to determine whether they met the eligibility criteria, and full texts of the selected articles were retrieved. RESULTS: Herein authors focused on the literature data concerning emerging biological therapeutic agents, namely anti-C5 monoclonal antibody (Eculizumab), anti-C1q monoclonal antibody, anti-T cell monoclonal antibody, anti-CD2 monoclonal antibody, anti L-selectin monoclonal antibody, anti- CD20 monoclonal antibody (Rituximab), anti-CD52 monoclonal antibody (Alemtuzumab) and cytokine targets. By far, none of these agents have been approved for the treatment of GBS by FDA. CONCLUSION: Literature findings represented in current review herald promising results for using these biological targets. Current review represents a summary of what is already in regards and what progress is required to improve the immunotherapeutic approach of treating GBS via future studies.

Medical Subject Headings

Animals; Biological Products (therapeutic use); Guillain-Barre Syndrome (therapy); Humans; Immunotherapy

Publication Date

1-1-2017

Publication Title

Current neuropharmacology

E-ISSN

1875-6190

Volume

15

Issue

7

First Page

938

Last Page

950

PubMed ID

27964705

Digital Object Identifier (DOI)

10.2174/1570159X14666161213114904

Recommended Citation

Motamed-Gorji, Nazgol; Matin, Nassim; Tabatabaie, Omidreza; Pavone, Piero; Romano, Catia; Falsaperla, Raffaele; and Vitaliti, Giovanna, "Biological Drugs in Guillain-Barré Syndrome: An Update" (2017). Neurology. 1500.
https://scholar.barrowneuro.org/neurology/1500